Biotech

All Articles

Merck ceases stage 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT program has actually suffered yet another problem. Months after shuttering a...

After a hard year, Exscientia folds in to Recursion

.After a year described through pipeline cuts, the shift of its CEO and also discharges, Exscientia ...

Cullinan, after $25M offer, return bispecific to Harbour

.Cullinan Rehab was actually thrilled sufficient along with Harbour BioMed's bispecific immune syste...

A closer check out Intense Biotech's Ferocious 15

.Within this full week's incident of "The Top Pipe," our company're diving in to Strong Biotech's ye...

Lilly faces stage 2 failing of tau-targeting med

.The confetti is still flying coming from Eli Lilly's celebration celebrating the commendation of Al...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our roundup of considerable leadership hirings, shootings an...

Lykos will definitely ask FDA to reevaluate its choice following rejection of MDMA therapy for post-traumatic stress disorder

.Complying with a poor presenting for Lykos Rehabs' MDMA prospect for trauma at a latest FDA consult...

AN 2 fifty percents census, ceases period 3 test after data disappoint

.AN2 Rehabs is actually reassessing its own service in feedback to poor midphase records, swearing t...

Merck spends $700M for bispecific, spying autoimmune opening and odds to challenge Amgen in cancer cells

.Merck &amp Co. is actually paying for $700 thousand upfront to test Amgen in a blood cancer market....

Gilead pays for J&ampJ $320M to go out licensing package for seladelpar

.With Gilead Sciences almost an FDA choice for its own liver disease medicine seladelpar, the provid...